Aslan to Start Global Phase III Trial of Lead Cancer Drug

Aslan Pharma of Singapore will start a global Phase III trial of its lead drug candidate, varlitinib, in patients with biliary tract cancer. The US FDA recently approved Aslan’s Investigational New Drug application for the drug, a small molecule pan-HER inhibitor. The two-arm trial, which will enroll 120 patients at 60 sites around the world, will be led by Milind Javle, MD, an expert in biliary tract cancer from Houston's MD Anderson Cancer Center. No treatments for biliary tract cancer are currently approved. More details.... Share this with colleagues: // //